The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) Journal Article
| Authors: | Smith, S. M.; Schoder, H.; Johnson, J. L.; Jung, S. H.; Bartlett, N. L.; Cheson, B. D. |
| Article Title: | The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) |
| Abstract: | Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma. © 2013 Informa UK, Ltd. |
| Keywords: | adult; cancer chemotherapy; treatment response; aged; clinical trial; drug activity; drug tolerability; fatigue; neutropenia; cancer recurrence; drug efficacy; drug safety; hypophosphatemia; side effect; outcome assessment; infection; anemia; thrombocytopenia; drug effect; hodgkin disease; hyperglycemia; pruritus; hypoalbuminemia; open study; b7 antigen; hodgkin lymphoma; motor neuropathy; reed sternberg cell; phase 2 clinical trial (topic); galiximab; cd80 |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 54 |
| Issue: | 7 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2013-07-01 |
| Start Page: | 1405 |
| End Page: | 1410 |
| Language: | English |
| DOI: | 10.3109/10428194.2012.744453 |
| PROVIDER: | scopus |
| PUBMED: | 23194022 |
| PMCID: | PMC5499151 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2013" - "CODEN: LELYE" - "Source: Scopus" |
